US · Healthcare · Biotechnology
EPS came in at -0.65 against a street estimate of -0.71 — a beat of 8.5%.
Analysts rate Alto Neuroscience, Inc. a strong buy (10 buy, 1 hold, 0 sell out of 11) with an average price target of $38.38.
| Fund | Stake |
|---|---|
| Alpha Wave Global LP | 9.45% |
| COMMODORE CAPITAL LP | 6.94% |
| BlackRock Inc | 5.40% |
| Perceptive Advisors LLC | 4.10% |
| Adage Capital Partners Gp LLC | 4.08% |
| Vanguard Capital Management, LLC | 3.54% |
| Spruce Street Capital LP | 3.45% |
| Vivo Capital, LLC | 3.08% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 ALTO NEUROSCIENCE, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Nicholas C. Smith receives $6,000,000 total retention payment: $3,000,000 payable with | 2026-08-27 |
| Quarterly report · Q2 2026 ALTO NEUROSCIENCE, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $243.7 million as of June 30, 2026 (up from $176.5 million at Decem | 2026-08-12 |
| Results announced · Q3 2026 ALTO NEUROSCIENCE Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Cash Position: $244.2 million as of June 30, 2026 (up from $177.0 million on December | 2026-08-12 |
| Material agreement · Q3 2026 ALTO NEUROSCIENCE, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company raised approximately $93.9 million in net proceeds from an underwritten regist | 2026-07-14 |
| Results announced · Q3 2026 ALTO NEUROSCIENCE, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and restricted cash: approximately $244.2 million as of June 3 | 2026-07-13 |
| Quarterly report · Q1 2026 ALTO NEUROSCIENCE, INC. - Q1 2026 QUARTERLY SUMMARY HEADLINE NUMBERS • Cash position: $263.8 million as of March 31, 2026 (up from $176.5 million at | 2026-05-13 |
| Proxy statement · Q2 2026 PROXY STATEMENT SUMMARY – ALTO NEUROSCIENCE, INC. WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 – Election of Directors: Vote to elect two Class II d | 2026-03-26 |
| Annual report FY2025 ALTO NEUROSCIENCE, INC. – FORM 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Company Status: Clinical-stage biopharmaceutical company; n | 2026-03-16 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alto Neuroscience, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.